ESMO 2017 Prostate Cancer - Results from #28

Viewing 41-41 of 41 articles

ESMO 2017: Randomized Controlled Trial Comparing Radiotherapy +/- Endocrine Therapy Versus Endocrine Therapy Alone for PSA Failure after Radical Prostatectomy: Japan Clinical Oncology Group Study JCOG0401

ESMO 2017: Prognostic Associations of PSA Decline with Survival, Radiographic Response and Progression in Chemotherapy-Naïve Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Enzalutamide

ESMO 2017: DNA repair gene panel mutations in young onset and aggressive v non-aggressive prostate cancer cases in the UK

ESMO 2017: Panel Discussion – Targeted Alpha Therapy

ESMO 2017: The Future of Targeted Alpha Therapy

ESMO 2017: Case Studies in mCRPC – Navigating the Increasingly Busy Waters

ESMO 2017: The Evolving Landscape of Treating Advanced Prostate Cancer

ESMO 2017: PROREPAIR-B: A prospective cohort study of DNA repair defects in metastatic castration resistant prostate cancer

ESMO 2017: Adding abiraterone acetate plus prednisolone or docetaxel for patients with high-risk prostate cancer starting long-term androgen deprivation therapy: directly randomized data from STAMPEDE

ESMO 2017: Lutetium-177 PSMA (LuPSMA) Theranostics Phase II trial: Efficacy, safety and QoL in patients with castrate-resistant prostate cancer treated with LuPSMA

ESMO 2017: Docetaxel with androgen suppression for high-risk localized prostate cancer patients who relapsed PSA after radical prostatectomy and/or radiotherapy: A randomized phase III trial

ESMO 2017: Benefits of Abiraterone Acetate Plus Prednisone When Added to Androgen Deprivation Therapy in LATITUDE on Patient Reported Outcomes

ESMO 2017: Patients with High Risk Prostate Cancer May Benefit “Equally” From Two New Treatments

1
2
3